Top

Tijdschrift voor Gerontologie en Geriatrie

Gepubliceerd in:

01-12-2012

Antistolling en atrium fibrilleren:

Consequenties voor de kwetsbare oudere, en de valrisicomythe

Auteur: Dr. T.A. Simmers

Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie | Uitgave 6/2012

Samenvatting

Atrium fibrilleren (AF) is de meest voorkomende ritmestoornis bij de mens. Incidentie neemt toe met de leeftijd, het aantal ischemische beroertes als gevolg van AF disproportioneel meer. Antistolling is om die reden een van de hoekstenen van behandeling. Gepercipieerde ernst van bloedingsrisico’s van antistolling maken echter juist dat de groep met hoogste risico, de bejaarde populatie, relatief wordt onderbehandeld. Dit artikel belicht beide risico’s voor de traditionele vitamine K antagonisten, alsook de nieuwe orale anti- coagulantia uit de families directe thrombine antagonisten en factor Xa antagonisten.

vorige artikel Fragiliteit bij jonge ouderen: meting met de Tilburg Frailty Indicator

volgende artikel Recent onderzoek

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8PubMedCrossRef

Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996;27:1760-4PubMedCrossRef

Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: aprospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34CrossRef

Go AS, Hylek M, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambu- latory patients with nonvalvular atrial fibrilla- tion: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927PubMed

Hylek EM, D’Antonio J, Evans-Monila C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice. The challenge of warfarin candidacy among hospi- talized elderly patients with atrial fibrillation. Stroke 2006;37:1075-80PubMedCrossRef

Tulner LR, Van Campen JP, Kuper IM et al. Reasons for undertreatment with anticoagu- lants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging 2010;27:39-50PubMedCrossRef

McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anti- coagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81PubMedCrossRef

Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-2429PubMedCrossRef

Camm AJ, Lip GYH, De Catarina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;aug 24 epub ahead of print

10.

Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Int Med 1999;131:492-501PubMed

11.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Int Med 2007;146:857-67PubMed

12.

Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Int Med 2009;51:297-305

13.

DiMarco JP, Flaker G, Waldo AL et al. Factors affecting bleeding risk during anticoagulation therapy in patients with atrial fibrillation: ob- servations from the Atrial Fibrillation Follow- up Investigation of Rhythm Management (AF- FIRM) study. Am Heart J 2005;149:650-6PubMedCrossRef

14.

Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6PubMedCrossRef

15.

Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA: a randomised controlled trial. Lancet 2007;370:493-503PubMedCrossRef

16.

Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabi- gatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51PubMedCrossRef

17.

Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anti- coagulation therapy (RE-LY) trial. Circulation 2011;123:2363-72PubMedCrossRef

18.

Diener H-C, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-63PubMedCrossRef

19.

Patel MR, Mahaffey KW, Garg J et al. Rivaroxa- ban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91PubMedCrossRef

20.

Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-5PubMedCrossRef

21.

Hankey GJ, Patel MR, Stevens SR et al. Rivar- oxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a subgroup analysis of ROCKET-AF. Lancet Neurol 2012;11:315-22PubMedCrossRef

22.

Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a subgroup analyss of the ARISTOTLE trial. Lancet Neurol 2012;11:503-11PubMedCrossRef

23.

Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Use of long-term anticoagulation is associated with traumatic intracranial hemorr- hage and subsequent mortality in elderly pa- tients hospitalised after falls: analysis of the New York State administrative database. J Trauma 2007;63:519-24PubMedCrossRef

24.

Bond AJ, Molnar FJ, Li M, Mackey M, Man-Son- Hing M. The risk of hemorrhagic complications in in-hospital patients who fall while receiving antithrombotic therapy. Thrombosis Journal 2005;3:1-6PubMedCrossRef

25.

Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are risk for falls. Arch Int Med 1999;159:677-85CrossRef

26.

Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7PubMedCrossRef

Titel: Antistolling en atrium fibrilleren:
Consequenties voor de kwetsbare oudere, en de valrisicomythe
Auteur: Dr. T.A. Simmers
Publicatiedatum: 01-12-2012
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie / Uitgave 6/2012
Print ISSN: 0167-9228
Elektronisch ISSN: 1875-6832
DOI: https://doi.org/10.1007/s12439-012-0044-7

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2012

Vijf jaar nadien: met de mond vol tanden?

Theater als contactmethode in de psychogeriatrische zorg: effecten op gedrag, stemming en kwaliteit van leven van mensen met dementie

Recente onderzoeksliteratuur

Signalementen

Fragiliteit bij jonge ouderen: meting met de Tilburg Frailty Indicator

Recent onderzoek